Research Topics
Species | Laurie H SehnSummaryAffiliation: British Columbia Country: Canada Publications
| Collaborators
|
Detail Information
Publications
Treatment of aggressive non-Hodgkin's lymphoma: a north American perspectiveLaurie H Sehn
British Columbia Cancer Agency, and University of British Columbia, Vancouver, Canada
Oncology (Williston Park) 19:26-34. 2005....- Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British ColumbiaLaurie H Sehn
Division of Medical Oncology and Pathology, British Columbia Cancer Agency, University of British Columbia, Vancouver, BC, Canada V5Z 4E6
J Clin Oncol 23:5027-33. 2005..We conducted a population-based analysis to assess the impact of this combination therapy on adult patients with DLBCL in the province of British Columbia (BC)... - Treatment of diffuse large B-cell lymphoma: a risk-based approachLaurie H Sehn
Division of Medical Oncology, British Columbia Cancer Agency, University of British Columbia, Vancouver, Canada
Clin Lymphoma Myeloma 7:S14-9. 2006..Alternative treatment strategies and newer therapies will need to be explored in the context of clinical trials... - The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOPLaurie H Sehn
Division of Medical Oncology, British Columbia Cancer Agency and the University of British Columbia, Vancouver, Canada
Blood 109:1857-61. 2007..In the era of R-CHOP treatment, the R-IPI is a clinically useful prognostic index that may help guide treatment planning and interpretation of clinical trials... - Rapid infusion rituximab in combination with corticosteroid-containing chemotherapy or as maintenance therapy is well tolerated and can safely be delivered in the community settingLaurie H Sehn
Division of Medical Oncology, British Columbia Cancer Agency, Vancouver, Canada
Blood 109:4171-3. 2007..The adoption of this 90-minute schedule as standard practice has had a positive impact on resource utilization... 
Paramount prognostic factors that guide therapeutic strategies in diffuse large B-cell lymphomaLaurie H Sehn
Division of Medical Oncology and the Centre for Lymphoid Cancer, British Columbia Cancer Agency and the University of British Columbia, Vancouver, BC, Canada
Hematology Am Soc Hematol Educ Program 2012:402-9. 2012....- Chemotherapy alone for localized diffuse large B-cell lymphomaLaurie H Sehn
Centre for Lymphoid Cancer, British Columbia Cancer Agency and the University of British Columbia, Vancouver, Canada
Cancer J 18:421-6. 2012..Ultimately, greater biologic insight into the heterogeneity of DLBCL will likely result in a personalized treatment approach that relies more on biologic characteristics than stage of disease... - A phase 1 study of obinutuzumab induction followed by 2 years of maintenance in patients with relapsed CD20-positive B-cell malignanciesLaurie H Sehn
British Columbia Cancer Agency Centre for Lymphoid Cancer and the University of British Columbia, Vancouver, BC, Canada
Blood 119:5118-25. 2012..This study was registered at www.clinicaltrials.gov (identifier NCT00576758)... - Bortezomib ADDED to R-CVP is safe and effective for previously untreated advanced-stage follicular lymphoma: a phase II study by the National Cancer Institute of Canada Clinical Trials GroupLaurie H Sehn
National Cancer Institute of Canada Clinical Trials Group, Kingston, Ontario, Canada
J Clin Oncol 29:3396-401. 2011..This is the first study to evaluate the safety and efficacy of bortezomib added to rituximab, cyclophosphamide, vincristine, and prednisone (R-CVP) in previously untreated advanced-stage FL... - Impact of concordant and discordant bone marrow involvement on outcome in diffuse large B-cell lymphoma treated with R-CHOPLaurie H Sehn
Centre for Lymphoid Cancer, British Columbia Cancer Agency, Vancouver Clinic, 600 W 10th Ave, Vancouver, British Columbia, Canada V5Z 4E6
J Clin Oncol 29:1452-7. 2011..We examined the significance of bone marrow involvement in patients treated in the current era of therapy including rituximab... - Early detection of patients with poor risk diffuse large B-cell lymphomaLaurie H Sehn
Division of Medical Oncology, Vancouver Clinic, British Columbia Cancer Agency and the University of British Columbia, Vancouver, Canada
Leuk Lymphoma 50:1744-7. 2009..These markers require further validation before clinical utility can be established. Continuous reassessment of clinical and molecular markers in the context of prospective clinical trials is necessary to ensure ongoing relevance... 
Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisoneNathalie A Johnson
British Columbia Cancer Agency, Vancouver, British Columbia, Canada
J Clin Oncol 30:3452-9. 2012..We investigated whether expression of MYC protein, with or without BCL2 protein expression, could risk-stratify patients at diagnosis...- International Prognostic Score in advanced-stage Hodgkin's lymphoma: altered utility in the modern eraAlden A Moccia
British Columbia Cancer Agency and University of British Columbia, Vancouver, British Columbia, Canada
J Clin Oncol 30:3383-8. 2012..The IPS has not been validated in a recently treated population in which outcomes have improved compared with historic results... - CHOP-R therapy overcomes the adverse prognostic influence of BCL-2 expression in diffuse large B-cell lymphomaKenneth S Wilson
Department of Medical Oncology, Vancouver Island Centre, University of British Columbia, BC, Canada
Leuk Lymphoma 48:1102-9. 2007..The addition of rituximab to CHOP chemotherapy negates the adverse prognostic influence of BCL-2 protein expression on progression free and overall survival in DLBCL... - Diffuse large B-cell lymphoma: reduced CD20 expression is associated with an inferior survivalNathalie A Johnson
Department of Pathology and Laboratory Medicine, British Columbia Cancer Agency, Vancouver, Canada
Blood 113:3773-80. 2009..CD20 and CD19 expression by FCM should be determined on all biopsies of patients with DLBCL because reduced CD20 expression cannot be reliably detected by IHC... - Prognostic implications of extranodal involvement in patients with diffuse large B-cell lymphoma treated with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisoneDavid Hui
Department of Medical Oncology, Vancouver Cancer Centre, Vancouver, British Columbia, Canada
Leuk Lymphoma 51:1658-67. 2010..In patients with DLBCL treated with R-CHOP, the presence of extranodal disease remains prognostic, whereas a primary extranodal presentation did not affect outcome... - MYC gene rearrangements are associated with a poor prognosis in diffuse large B-cell lymphoma patients treated with R-CHOP chemotherapyKerry J Savage
Department of Medical Oncology, British Columbia Cancer Agency, 600 West 10th Ave, Vancouver, BC, Canada V5Z4E6
Blood 114:3533-7. 2009..In the R-CHOP treatment era, MYC+ DLBCLs have an inferior prognosis. Treatment regimens similar to those used in Burkitt lymphoma may be more appropriate in this patient population and need to be prospectively tested... - Correlations between BCL6 rearrangement and outcome in patients with diffuse large B-cell lymphoma treated with CHOP or R-CHOPJesse Shustik
Division of Medical Oncology, Laboratory Medicine, BC Cancer Agency, University of British Columbia, Vancouver, Canada
Haematologica 95:96-101. 2010..We analyzed the effect of the BCL6 rearrangement on survival in patients with diffuse large B-cell lymphoma treated with CHOP and CHOP plus rituximab (R-CHOP)... - Population-based analysis of incidence and outcome of transformed non-Hodgkin's lymphomaAbdulwahab J Al-Tourah
Division of Medical Oncology, Fraser Valley and Vancouver Cancer Centers and the Department of Pathology and Biostatistics, British Columbia Cancer Agency and the University of British Columbia, Vancouver, BC, Canada
J Clin Oncol 26:5165-9. 2008..To assess the incidence and predictive factors for development of transformed lymphoma in a population-based series of patients with follicular lymphoma (FL)... - CD20 mutations involving the rituximab epitope are rare in diffuse large B-cell lymphomas and are not a significant cause of R-CHOP failureNathalie A Johnson
Clinical Professor of Pathology, Department of Pathology, British Columbia Cancer Agency, 600 W 10 Avenue, Vancouver, BC, V5Z 4E6, Canada
Haematologica 94:423-7. 2009..CD20 protein-negative relapses occur after R-CHOP therapy but their clinical relevance is unknown... - Treating limited-stage nodular lymphocyte predominant Hodgkin lymphoma similarly to classical Hodgkin lymphoma with ABVD may improve outcomeKerry J Savage
Department of Medical Oncology, University of British Columbia, Vancouver, BC, Canada
Blood 118:4585-90. 2011..0024), and OS (93% vs 84%, P = .074) favored the ABVD treatment era compared with the RT alone era. Treating limited-stage NLPHL similarly to CHL may improve outcome compared with the use of radiation alone... - Diffuse large B-cell lymphoma with involvement of the kidney: outcome and risk of central nervous system relapseDiego Villa
British Columbia Cancer Agency, 600 West 10 Ave Vancouver, BC V5Z4E6, Canada
Haematologica 96:1002-7. 2011..We reviewed the clinical features, risk of central nervous system involvement, and survival of patients with diffuse large B-cell lymphoma with involvement of the kidney at diagnosis... - Prognostic factors in follicular lymphomaThomas Relander
Department of Pathology, British Columbia Cancer Agency and University of British Columbia, Vancouver, British Columbia, Canada
J Clin Oncol 28:2902-13. 2010..There is a need for useful biomarkers for prediction of the disease course of single patients to individualize therapy, especially in the new era of chemoimmunotherapy... - Pathogenesis of follicular lymphomaRobert Kridel
Center for Lymphoid Cancer, BC Cancer Agency, Department of Pathology and Laboratory Medicine, and Division of Medical Oncology, University of British Columbia, Vancouver, British Columbia, Canada
J Clin Invest 122:3424-31. 2012..Lastly, crosstalk between neoplastic B cells and non-neoplastic immune and stromal cells in the microenvironment plays an important role in sustaining tumor cell growth, cultivating immune privilege, and promoting transformation... - Whole transcriptome sequencing reveals recurrent NOTCH1 mutations in mantle cell lymphomaRobert Kridel
Centre for Lymphoid Cancer, British Columbia Cancer Agency, 675 W 10th Ave, Vancouver, BC, Canada
Blood 119:1963-71. 2012..In summary, we have identified recurrent NOTCH1 mutations that provide the preclinical rationale for therapeutic inhibition of the NOTCH pathway in a subset of patients with MCL... - Limited-stage diffuse large B-cell lymphoma treated with abbreviated systemic therapy and consolidation radiotherapy: involved-field versus involved-node radiotherapyBelinda A Campbell
Department of Radiation Oncology and Cancer Imaging, Peter MacCallum Cancer Centre, Melbourne, Australia
Cancer 118:4156-65. 2012..We retrospectively review the long-term outcomes of limited-stage DLBCL treated with abbreviated systemic therapy and radiotherapy focusing on field size: IFRT versus INRT... - Gene expression predicts overall survival in paraffin-embedded tissues of diffuse large B-cell lymphoma treated with R-CHOPLisa M Rimsza
Department of Pathology, University of Arizona, Tucson, USA
Blood 112:3425-33. 2008.... - Paraffin-based 6-gene model predicts outcome in diffuse large B-cell lymphoma patients treated with R-CHOPRaquel Malumbres
Department of Medicine, Division of Hematology Oncology and Molecular and Cellular Pharmacology, Sylvester Comprehensive Cancer Center, University of Miami, FL 33136, USA
Blood 111:5509-14. 2008..008). These findings demonstrate that the prognostic value of the 6-gene model remains significant in the era of R-CHOP treatment and that the model can be applied to routine FFPE tissue from initial diagnostic biopsies... - LMO2 protein expression predicts survival in patients with diffuse large B-cell lymphoma treated with anthracycline-based chemotherapy with and without rituximabYasodha Natkunam
Department of Pathology, Division of Oncology, Stanford University School of Medicine, Stanford, CA, USA
J Clin Oncol 26:447-54. 2008..Here, we tested the prognostic impact of LMO2 protein expression in DLBCL patients treated with anthracycline-based chemotherapy with or without rituximab...